Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target
Tip Ranks·- LifeSci Capital's Francois Brisebois maintained a buy rating for Larimar Therapeutics with a target price of $25.00. - The rating is supported by the steady progress of nomlabofusp towards approval and its lasting clinical effects, indicating significant functional improvements in patients. - Citi also upheld a buy rating on the stock with a target price of $14.00, highlighting confidence despite the company's limited cash flow.